VLT Biopharma Obtains an Orphan Drug Designation
The spin-off of the University of Valencia will develop a treatment for Myotonic Dystrophy
Valentia Biopharma, a company that emerged from the University of Valencia, has obtained an orphan drug designation for VLT015. The European Commission has recognized this way a compound for the treatment of myotonic dystrophy, a rare disease to which Valentia Biopharma can provide solutions.
Mètode visits the facilities of this biotech company, located in the Science Park of the University of Valencia, to chat with Manuel Pérez, M. Carmen Álvarez and Rubén Artero. They explain the concept of rare diseases, myotonic dystrophy and orphan drugs, and they tell us about their experiments with fruit flies and what these insects reveal.
[English subtitles are available for this video.]
